Not active patients are more likely to be diagnosed with PPMS (56% vs. 36%), but designation of not active SPMS does not differ between groups. Neurologists describe more not active patients as having stable disability (48% vs. 37%) and reportedly less disability (mean Expanded Disability Status Scale score: 5.8 vs 7.3; median: 5.0 vs. 7.0) than active patients. Among patients reported to have disability progression, progression is believed to occur independent of relapse activity (PIRA) for most patients in both groups (94% vs. 86%).

Not active patients less frequently switched DMTs in the past year (20% vs. 42%) and are more often on their first DMT (52% vs. 37%) compared to active patients. More not active than active patients are currently prescribed ocrelizumab (49% vs. 35%), with disability progression delay (29% vs. 22%) more influential in therapy selection for not active patients. Neurologists rate willingness to prioritize high efficacy above safety risk when selecting a therapy lower (6.7 vs. 7.3 on 10-point scale) for not active patients.